Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30

$0.61−0.06 (-8.25%)

Close on Nov 13, 2026Market cap $354.83KP/E –Yield –

Virax Biolabs gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2026 it was 61.9%, against -838.2% the year before. The highest annual figure on record is 61.9% in fiscal 2026.

Period	Period end	Value	Change (pts)
FY2026	Mar 31, 2026	61.9%	+900.1
FY2025	Mar 31, 2025	-838.2%	−870.6
FY2024	Mar 31, 2024	32.3%	+48.3
FY2023	Mar 31, 2023	-15.9%	−8.3
FY2021	Mar 31, 2021	-7.6%	–

Parsed from the XBRL in Virax Biolabs's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Jun 26, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VRAX.

Operating margin-51515.2% · median -913114.9%

Net margin-40439.1% · median -871894.3%

Advertisement
300 × 250

See a number that looks wrong?